Global Acne Drugs Market

The drugs for hormonal replacement therapy market consists of sales of drugs for hormonal replacement therapy and related services. The drugs for hormonal replacement therapy are used to treat patients with growth hormone deficiency caused due to conditions such as dwarfism or menopause (a condition which describes changes a woman goes through when her menstruating cycle stops). The drugs for hormonal replacement therapy help to replace low level hormones from the body, maintain growth hormone deficiency and prevent women from vaginal dryness, mood swings, weakening of bones and others. The main types of drugs for hormonal replacement therapy are estrogen replacement therapy, human growth hormone (HGH) replacement therapy, thyroid replacement therapy and testosterone replacement therapy. The various routes of administration are oral, parental and others which are distributed hospital pharmacies, retail pharmacies and online pharmacies. The therapies are applied for hypothyroidism, male hypogonadism, growth hormone deficiency, menopause and others. The global drugs for hormonal replacement therapy market size is expected to grow from $11.13 billion in 2021 to $12.00 billion in 2022 at a compound annual growth rate (CAGR) of 7.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global hormonal replacement therapy market size is expected to reach $15.25 billion in 2026 at a CAGR of 6.2%. Increasing population of aging and postmenopausal women is driving the drugs for hormonal replacement therapy market growth. Hormonal replacement therapy drugs such as Estrogen, Progestin and others are used to treat medical conditions caused due to menopausal conditions. According to a report by The Indian Menopause Society, New Delhi, in India there are 65 million women over the menopausal age affected with menopausal symptoms. According to European Menopause and Andropause Society (EMAS) report, women aged over 60 are expected to reach over 1 billion by 2050. In South Korea, the female population is expected to exceed male population by 2060, out of which 59.6% of female population is expected to suffer from postmenopausal symptoms. Thus, growing women population suffering from menopausal symptoms and aging population drives the market for hormonal replacement therapy drugs market. Increasing occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder growth of the hormonal replacement therapy drugs market. The side effects include vagina dryness, irregular heartbeat, breast swelling, osteoporosis (weakening of bones) and other effects when women undergo hormonal replacement therapy. High dosage of drugs for hormonal replacement therapy may cause rapid heartbeat, bloating (a build-up of gas in the stomach and intestines), nausea, indigestion, vaginal bleeding, blood clots, heart attack, breast cancer and others. According to an online study, decrease in the intake of drugs for combined hormone therapy showed a decrease in breast cancer cases by 126,000 and cardiovascular disease cases by 76,000. Thus, the increasing side effects of drugs hinders the growth of drugs for hormonal replacement therapy. Companies in the industry are increasingly developing of drugs for hormonal replacement therapy with better safety profiles and novel drug delivery mechanisms. The drug delivery mechanisms include transdermal estrogen, varginal estrogen and others. Transdermal estrogen drug delivery is in the form of estradiol transdermal gel, patch, and spray that are used to treat symptoms of menopause, vaginal dryness, itching, burning and others occur due to low estrogen levels. Varginal estrogen in the form of cream, vaginal ring, vaginal tablets are used to get the hormone estrogen into the system. For instance, Novo Nordisk, a multinational pharmaceutical company provides novel drug delivery mechanisms and low dose drugs for hormonal replacement therapy (HRT) to cater to the rising demand of patient needs. Some of the brands offering of novel drugs include Climara, Divigel, Elestrin, Esclim, Estraderm, Estrasorb, EstroGel, Evamist, Oesclim, Rhoxal-Estradiol Derm 50, Vivelle 100 Mcg, Estradot Transdermal Therapeutic System and others. Department Of Health And Human Services of Food And Drug Administration (FDA), a federal agency, is a regulatory body monitoring, controlling and regulating the drugs for hormonal replacement therapy market. For instance, FDA's Department Of Health And Human Services has revised the requirements of specific hormone-containing drug products for human use. These hormones include estrogens, progestin's, androgens, anabolic steroids, adrenal corticosteroids, and synthetic analogs. The purpose of the revisal of existing regulations by FDA is to establish effectiveness and ensure safety for any over-the-counter drug use of these ingredients. Major players in the drugs for hormonal replacement therapy market are Novartis AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Abbott, Mylan Laboratories, Merck & Co, Hisamitsu Pharmaceutical Co Inc, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Noven Pharmaceuticals Inc., Orion Pharma AB, Allergan Plc, QuatRx Pharmaceuticals, Wyeth, Amgen Inc., Roche, Genentech and TherapeuticsMD. North America was the largest region in the drugs for hormonal replacement therapy market in 2021. The Middle East is expected to be the fastest growing region in the global hormonal replacement therapy drug market during the forecast period. The regions covered in the global hormonal replacement therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drugs for hormonal replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global drugs for hormonal replacement therapy market is segmented - 1) By Therapy Type: Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Application: Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause, Others 4) By Route of Administration: Oral, Parental, Others

The acne drugs market consists of sales of prescription acne drugs (Salicylic acid, Retin-A Micro, Onexton, and Solodyn) and related OTC non-prescription products (cleansers, lotions, gels, toners, masks and pads containing acne drugs-fighting ingredients) which are used to treat skin diseases such as acne drugs vulgaris and acne drugs rosacea. Market in this report does not include the sales of drugs used for dermatitis and psoriasis. The global acne drugs market size is expected to grow from $5.03 billion in 2021 to $5.36 billion in 2022 at a compound annual growth rate (CAGR) of 6.7%.The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global acne drug market is expected to reach $6.55 billion in 2026 at a CAGR of 5.2%. An increase in the disposable income of people is one of the major drivers in the acne drugs market. An increase in the disposable income is usually due to an improved economy leading to increased wages and salaries boosting healthcare expenditure. According to the Office For National Statistics (UK), in 2020, the average household disposable income in UK was £30,800 ($37,830), an increase of 2.3% from 2019. Rise in disposable income increased expenditure on facial care products is expected to continue, thereby driving the market in the forecast period. Acne is a major problem worldwide; close to 90% of people suffer from some sort of acne. In America alone, close to 12 million people suffer from a severe acne problem, that can lead to scarring of the skin if left untreated, as a result many people purchase acne care drugs and products. The presence of alternatives for acne treatment is one of the restraints on the acne drugs market. Due to availability of multiple alternatives, patients tend to choose one amongst many options on the basis of price, side effects, duration and many more. This increases the competition and hence, the competition cuts down a significant portion of business for the acne drugs market. For example, some of the alternatives for the acne drugs treatment apart from acne drugs are Ayurveda, home remedy, laser and photodynamic therapy and extraction of whiteheads and blackheads using special tools like needles and forceps. Combination therapy is the latest trend in the acne drugs market. Combination therapy is the process of combining two drugs with different mechanisms of action, such combinations of medication have a better efficacy and adherence when compared with monotherapy (the use of only a single drug by itself). The combination of a topical retinoid drug, which unclogs the pores, along with an antimicrobial drug, which is used to treat an infection is being used to treat acne drugs. Example of combination therapy includes: Epiduo, Acanya, Ziana and Benzamycin produced by Galderma, Allergan, Medicis and Atrix respectively. The stringent regulations concerning the usage of drugs to treat acne has an impact on the acne drugs market. The regulations have become stringent due to the various side-effects and adverse events caused during the course of treatment. In India, the Central Drugs Standard Control Organization (CDSCO) has issued a warning regarding the safety guidelines concerning the use of the oral drug, Isotretinoin. The CDSCO has directed the State and Union Territories’ drugs controllers to check the labeling of Isotretinoin drug and make the end users aware of the serious birth defects the drug may cause. Further, the Subject Expert Committee (SEC) for Dermatology and Allergy has recommended that the drug should be sold only on the prescription of a dermatologist, manufacturers should provide a package insert in local languages and the retail chemists should maintain the details of retail sale of the drug. Hence, these strict guidelines and regulations would impact the growth of acne drugs market. In March 2019, Allergan acquired Envy Medical Inc. at an undisclosed price. This deal will help Allergan reinforce their goal towards providing customers with enhanced skin care solutions. Envy Medical's technology used in skin resurfacing procedures like Dermalinfusion, which is a non-surgical, non-invasive skin resurfacing system will immensely help Allergan gain a strong presence in the acne drugs market. Allergan plc is a pharmaceutical company established in 1948 and headquartered in Dublin, Ireland. Major players in the acne drugs market are Allergan plc, Galderma S.A., Valeant Pharmaceutical International Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc., GlaxoSmithKline Plc., Bayer AG, Stiefel Laboratories Inc., Ranbaxy Laboratories Limited, Pfizer Inc., Sun Pharmaceutical Industries Limited, Mayne Pharma Group Limited, Mylan N.V., Cipher, Daiichi Sankyo Company, Ltd, Guthy-Renker LLC, Medicis Pharmaceutical Corporation, Foamix Pharmaceuticals, BioPharmX, In, Roche Holding AG, F. Hoffmann-la Roche Ltd, Anterios Inc., AndroScience, Oculus Innovative Sciences, Aqua Pharmaceuticals, Skinvisible Pharmaceuticals and Prestium Pharma Inc. North America was the largest region in the acne drugs market in 2021. The Middle East is expected to be the fastest growing region in the global acne market during the forecast period. The regions covered in the global acne medication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the acne drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global acne drugs market is segmented - 1) By Type: Inflammatory Acne Drugs, Non-Inflammatory Acne Drugs 2) By End-User: Hospitals and Clinics, Pharmacies and Drug Stores, Ambulatory Surgical Centres 3) By Therapeutic Class: Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide

The dermatology medical lasers market consists of sales of dermatology medical lasers and related services by companies that manufacture them. Dermatology medical lasers are used in the treatment of medical conditions related to the skin and for cosmetic procedures such as scar removal, skin rejuvenation, skin lightening, hair removal, and tattoo removal. The main devices of dermatology medical lasers are surgical lasers and vascular lasers. Vascular laser is a type of device that is utilized to treat vascular lesions, like port wine stains, spider veins, rosacea, and wrinkles by targeting the vessels in these specific areas. The various applications involved are cancer, hair removal, tattoo removal, resurfacing, and others that are used by various end-users such as hospitals, skincare clinics, and cosmetic surgical centers. The global dermatology medical lasers market size is expected to grow from $2.56 billion in 2021 to $3.04 billion in 2022 at a compound annual growth rate (CAGR) of 19%. The global dermatology medical lasers market size is expected to grow to $5.82 billion in 2026 at a compound annual growth rate (CAGR) of 17.6%. The growing demand for cosmetic procedures is expected to drive the dermatology medical lasers market. There has been an increase in the number of people opting for cosmetic procedures to enhance the appearance levels and treatment of defects on the skin. According to the American Society of Plastic Surgeons data, $16.7 billion was spent on cosmetic procedures in the U.S. in 2020. The poll also revealed that 11% of women surveyed said they are more interested in cosmetic plastic surgery or non-surgical procedures than before COVID-19 . Dermatology lasers are used in cosmetic procedures such as removal of fine lines, wrinkles, skin tightening, pigmented lesions, precancerous lesions, vascular lesions, tattoos, hair removal, acne scars, and others. Hence, the growing demand for cosmetic procedures among users aids in the growth of the dermatology medical lasers market. Alternatives for laser skin treatment are expected to hinder the dermatology medical lasers market. The growing popularity of alternative methods of skin treatment such as the use of drugs, chemical treatment, microneedle, and Botox surgery is expected to hinder the growth of the market. For instance, as per the survey by eMediHealth of 64 dermatologists from October to November 2019, drug therapy such as Isotretinoin and retinoids have a higher success rate for acne treatment with 75% dermatologists preferring it over laser therapy. Thus, the demand for alternatives is expected to restrain the market growth. Companies are increasingly investing in Picosecond Lasers for skin treatments other than tattoo removal as they have found their use in the treatment of acne, skin lightening, and skin tightening. For instance, in February 2019, LaserOptek received FDA clearance for its PicoLO picosecond laser device used for the treatment of scars and skin rejuvenation. Therefore, the use of picosecond lasers in dermatological processes is expected to be the new trend in the dermatology medical lasers market. In March 2020, SemiNex Corporation, a U.S-based high-diode manufacturer, announced its collaboration with Dermal Photonics Corporation, a manufacturer of Nira skincare - a professional home laser technology. Through this collaboration, SemiNex Corporation plans to enhance home-based lasers for dermatology procedures. Dermal Photonics is a US-based medical device company. Major players in the dermatology medical lasers market are Cynosure, Peninsula, Miracle Laser, Syneron, Shenzhen GSD, Sinocheren, Fotona, Alma Lasers Ltd, and Cutera. North America was the largest region in the dermatology medical lasers market in 2021. Asia Pacific was the second largest region in the global dermatology medical lasers market during the forecast period. The regions covered in the global dermatology medical lasers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the dermatology medical lasers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global dermatology medical lasers market is segmented - 1) By Device: Surgical Lasers , Vascular Lasers 2) By End-users : Hospitals, Skin Care Clinics, Cosmetic Surgical Centres 3) By Application: Cancer, Hair Removal, Tattoo Removal, Resurfacing, Other Applications

The cosmetic lasers market consists of sales of cosmetic lasers by entities (organizations, sole traders, and partnerships) that manufacture cosmetic lasers used during cosmetic surgeries. A cosmetic laser is a device used to reduce facial wrinkles and skin irregularities, such as acne scars or blemishes. Cosmetic lasers are also used for removing unwanted hair from the body by beaming highly concentrated light into the hair follicles. It is used to treat In medical conditions, it is used to treat such as sagging eyelid skin, aging skin problems, wrinkles on the face birthmarks, fine lines, and dark circles. The main types of cosmetic lasers are standalone lasers, multiplatform lasers, and the models include pulsed dye laser (PDL), yttrium aluminum garnet (YAG) laser, carbon dioxide laser, erbium, intense pulsed light (IPL), radiofrequency, infrared, others. Standalone lasers have a single wavelength and a small variety of applicators used for treating a narrow range of indications. The multiplatform lasers use a handpiece with a small laser rod positioned inside having different wavelengths for a range of indications. The cosmetic laser is used by hospitals, skincare clinics, cosmetics surgical centers and is applied in various areas including hair removal, skin resurfacing, vascular lesions, scar and acne removal, body contouring, others. The global cosmetic lasers market size is expected to grow from $2.02 billion in 2021 to $2.41 billion in 2022 at a compound annual growth rate (CAGR) of 19.1%. The global cosmetic laser market is expected to grow to $4.95 billion in 2026 at a CAGR of 19.7%. Rising medical tourism supported the growth of the cosmetic lasers market over the historic period. The wide availability of better quality and low costs treatment options is increasing demand for medical tourism which provides better facilities and experienced doctors for better treatment and care, at an economical price. The rise in medical tourism, especially cosmetic surgery medical tourism is likely to escalate the demand for cosmetic lasers. For instance, according to foreign tourist arrivals (FTAs) in India, the medical visas recorded in 2019 were 2,33,918. Medical visitors come to the country for its top-line cancer treatment centers and expertise in cosmetic surgery. Therefore, the upraising medical tourism industry is predicted to augment the demand for cosmetic lasers. The stringent regulations for cosmetic laser products for approval and marketing could be expected to be a restraint for the market in the forecast period. The laser device manufacturers have to comply with several regulations relating to radiation safety, device efficiency and performance, and other FDA guidelines on major hazard classes. The stringent regulatory processes and standards for cosmetic lasers delay the time required for the device to get to the market which could act as a restraint in the forecast period. The companies are increasingly focusing on developing innovative and technologically advanced products to meet the requirement of end-users, expand the company product portfolio, and maximize company sales. For instance, in January 2020, Lumenis, an Israel-based manufacturer of minimally-invasive clinical solutions for aesthetic, surgical, and ophthalmology markets launched LightSheer Quattro, a product that offers hair removal treatment for all skin types. In 2019, India-based medical and aesthetic solutions company, Alma Medical launched a novel device for hair removal named Saprano Titanium, which is quicker, painless, and covers a greater area using multiple wavelengths. In December 2019, US-based private equity company, Potomac Equity Partners, through its portfolio company, Laser MD Medspa, acquired Laser Gentle Medspa for an undisclosed amount. Through this acquisition, Laser MD Medspa expands its geographical presence and gains access to a full suite of cosmetic and aesthetic treatments, including laser hair removal services. Laser Gentle Medspa is a US-based company specializing in laser hair removal, skin rejuvenation, body contouring, and others. Major players in the cosmetic lasers market are Cutera Inc, Cynosure Inc, Lumenis, Aerolase Corporation, ALMA LASERS LTD, Sciton Inc, Syneron Candela, Solta Medical International Inc, ElEn SpA, Lynton Lasers Ltd, and Medicure Group Of Companies. The regions covered in the global cosmetic lasers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cosmetic laser market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global cosmetic lasers market is segmented - 1) By Type: Standalone Lasers, Multiplatform Lasers 2) By Modality: Pulsed Dye Laser (PDL), YAG Laser, Carbon Dioxide Laser, Erbium, Intense Pulsed Light (IPL), Radiofrequency, Infrared, Others 3) By Application: Hair Removal, Skin Resurfacing, Vascular Lesions, Scar and Acne Removal , Body Contouring, Others 4) By End-User: Hospitals, Skin care clinics, Cosmetics Surgical Centre

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of bispecific monoclonal antibodies and related services. Bi-Specific MAbs are artificial proteins that can bind two or more antigens into a single product. Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and finds its applications in the field of drug delivery and cancer immunotherapy. The main types of bi-specific MAbs are catumaxomab (removab), blinatumomab, duligotumab, SAR 156597. Catumaxomab is a rat-mouse hybrid monoclonal antibody used to treat malignant ascites, a condition that occurs in people who have metastasizing cancer. The various product types include in vivo, in vitro that are used for the treatment of cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases and others. The bispecific monoclonal antibodies are used by hospitals, research institutes, others. The global bi-specific MAbs market size is expected to grow from $3.80 billion in 2021 to $5.13 billion in 2022 at a compound annual growth rate (CAGR) of 34.9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The bispecific monoclonal antibodies market is expected to reach $11.64 billion in 2026 at a CAGR of 22.7%. The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bi-specific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective over monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression. According to the World Health Organization, cancer is the leading cause of death worldwide and is responsible for around 10 million deaths in 2020. Additionally, according to the Centers for Disease Control and Prevention, chronic diseases are among the most prevalent diseases with 6 out of 10 adults suffering from at least one chronic disease in the USA. Therefore, a rising number of chronic diseases including cancer is anticipated to propel the demand for bi-specific MAbs market to treat these diseases effectively. The availability of various alternative treatment methods for cancer is expected to limit the growth of the bispecific monoclonal antibodies market. Alternative cancer treatment therapies and methods used for the treatment of cancer including dietary treatments, acupuncture, homeopathy, and herbal remedies are gaining popularity in recent years attributed to side effects of chemotherapeutic anticancer agents. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many of the herbs used in Ayurveda have anti-cancer properties, for example, andrographis paniculata. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source and developing nations are using the benefits of natural compounds for therapeutic purposes. Therefore, this affects the biologic sales, and hence impacting the bi-specific MAbs market. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027, growing at a CAGR of 14% during the forecast period. The less expensive alternative medicines increase competition for the biologics market, thereby, hindering the growth of the bi-specific MAbs market in the near future. Companies in the bi-specific MAbs market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. For instance, in June 2020, AbbVie Inc., a US-based biopharmaceutical company entered into a collaboration agreement with Genmab A/S, a Danish biotechnology company, to develop and commercialize antibody therapeutics for cancer treatment. The companies together will work on three early-stage bispecific antibody candidates of Genmab A/S including DuoHexaBody-CD37, epcoritamab, and DuoBody-CD3x5T4 along with discovering new antibody therapeutics. Moreover, in July 2020, Atreca, Inc., a US-based clinical-stage biotechnology company, and Xencor, Inc. entered into a strategic partnership to develop, discover, and commercialize Novel T cell engaging bispecific antibodies as potential therapeutics for oncology treatment. Xencor, Inc. is a US-based biopharmaceutical company developing engineered monoclonal antibodies for cancer and autoimmune disease treatment. In August 2020, AbCellera, a biotechnology firm based in Canada, completed the acquisition of OrthoMab bispecific platform from Dualogics for an undisclosed amount. The acquisition integrated OrthoMab into AbCellera existing technology stack, which provided the industry with a rapid and complete solution for generating tailored, stable, and developable bispecific antibodies Dualogics is a US-based biotechnology company specialized in protein engineering for improving antibody therapeutics. Major players in the bi-specific MAbs or bispecific monoclonal antibodies market are Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Inc., Bistro-Myers Squibb. Mylan N.V., Daiichi Sankyo Company Ltd. and Abbott. The regions covered in the bi-specific MAbs or bispecific monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bi-specific MAbs or bispecific monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global bi-specific MAbs market is segmented - 1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597 2) By Product Type: In Vivo, In Vitro 3) By Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, Others 4) By End Use: Hospitals, Research Institutes, Others

The biosimilar interleukins market consists of sales of interleukin biosimilars generated by the establishments that manufacture interleukin biosimilars that are used to treat various autoimmune diseases. Interleukin is a substance derived from white blood cells that enhances infection activity and is used to fight certain types of cancer. The different types of biosimilar interleukins are IL-17, IL-23, IL-1, IL-5, IL-6, others. Interleukin 17 is a pro-inflammatory cystine knot cytokine family. In response to IL-23 stimulation, they are produced by a subset of T helper cells known as T helper 17 cells. The different applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (IBD), others and is distributed through various channels such as hospital pharmacies, online pharmacies, retail pharmacies, clinics, research institutes. The global biosimilar interleukins market size is expected to grow from $1.42 billion in 2021 to $2.01 billion in 2022 at a compound annual growth rate (CAGR) of 40.9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar interleukins market is expected to reach $7.52 billion in 2026 at a CAGR of 39.1%. The increasing prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market in the forecast period. Autoimmune disorders are conditions in which the immune cells cannot distinguish healthy cells from potentially dangerous antibodies. Biologic drugs such as anti-interleukin antibodies have shown significant clinical benefit in regulating the cells, and in directing proliferation, activation, and migration of the cells. According to the Johns Hopkins University report published in 2021, autoimmune illnesses impacted around 3% of the population in the United States, or about 10 million individuals. Therefore, the increasing prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins market and is expected to drive the growth of the market. The regulatory framework around the approval of interleukin biosimilars hampers the growth of the market. Biosimilars are manufactured with changes in the manufacturing process impacting the physicochemical and functional properties of a biologic drug and it is impractical to create an exact copy of the biologic drug. This compels the manufacturers to demonstrate biosimilarity between interleukin biosimilar and the biologic drug to prove that there are no clinically meaningful differences. This calls for extensive comparative analytical, nonclinical, and clinical assessments to get approval from the medical authorities, thereby, increasing the cost of the approval process and restraining the growth of the market. In January 2020, Sanofi, a France-based pharmaceutical company, acquired Synthorx, Inc. for $2.5 billion. This acquisition enhances Sanofi’s position as an emerging leader in the area of oncology and immunology. Synthorx, Inc. is a US-based biotechnology company focused on developing interleukins for people suffering from cancer and autoimmune disorders. Major players in the biosimilar interleukins market are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech, and Sunshine Guojian Pharmaceutical. The regions covered in the biosimilar interleukins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global biosimilar interleukins market is segmented - 1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6 2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Others 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

Anti-Asthmatic and COPD Drugs Definition

The anti-asthmatics and COPD drugs market consists of sales of anti-asthmatics and COPD drugs by entities (organizations, sole traders and partnerships) that manufacture anti-asthmatics and COPD drugs which are used to prevent and treat asthma and chronic obstructive pulmonary disease (COPD). The anti-asthmatics and COPD drug industry includes establishments that manufacture anti-asthmatics and COPD drugs such as bronchodilators, anti-inflammatory drugs, monoclonal antibodies and combination drugs. Asthma is a condition that causes the airways in the body to narrow and swell and generate extra mucus. This can make breathing difficult, resulting in coughing, wheezing on exhalation and shortness of breath. Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes airflow obstruction in the lungs. Breathing difficulties, cough, mucus production and wheezing are all symptoms.

The body lotions market consists of the sales of body lotions. Body lotions are a smooth liquid preparation designed to be applied to the skin for medicinal, cosmetic purposes, or protective purposes. For example, sunscreens, are a substance that protects from the sun's ultraviolet (UV) radiation and thus helps against sunburns. The main types of body lotion are dry skin body lotion, oily skin body lotion, normal skin body lotion, and other types. Body lotions are a smooth liquid preparation designed to be applied to the skin for medicinal, cosmetic purposes, or protective purposes. These are applied by men, women, and babies and segmented by channel into direct sales and distributors. The global body lotions market is expected to grow from $55.3 billion in 2021 to $63.9 billion in 2022 at a compound annual growth rate (CAGR) of 15.5%. The body lotion market is expected to grow to $98.9 billion in 2026 at a CAGR of 11.5%. Rapid growth in the millennial population is expected to drive the body lotions market. According to Cosmetics Europe, the cosmetics and personal care business adds at least €29 billion (USD 33.14 billion) to the European economy each year, and the number of individuals using cosmetics products is rapidly expanding, surpassing 500 million in Europe. By 2025, millineals are expected to constitute nearly three-quarters of the global workforce. As millennials will represent a large part of the global workforce and play a major role in driving the current economy, their preferences and shopping habits will be an important driving factor for the lotions market. Strict regulations by government agencies on the use of certain ingredients in making cosmetics is expected to act as a key restraint on the market. These ingredients are prohibited due to their toxicity and their use may lead to various skin diseases. The EU Cosmetics Regulations lists substances that cannot be used and also those that can be used only in specified circumstances. Similarly, the US Food and Drug Administration (FDA) prohibits or restricts a list of ingredients in cosmetics. These prohibited substances include bithionol, chloroform, mercury compounds, methylene chloride, vinyl chloride, and chlorofluorocarbon propellants. The demand for multi-benefit combinations has been increasing rapidly. Products such as foundations with anti-aging serums, sun screen lotions, nail polish with UV protection, and anti-aging claims are introduced into the market. Multi-benefit solutions are expected to continue to penetrate further into different categories such as hair care with anti-aging or fragrance to lipsticks with lip care. Major players in the body lotions market are Aveeno, Cetaphil, Olay, Alba Botanica, Avalon Organics, Clarins, Crabtreeand Evelyn, Hempz, Murad, and L'Oréal S.A. Asia Pacific was the largest region in the body lotion market in 2021. North America was the second-largest region in the body lotions market. The regions covered in the body lotions market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the body lotions market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The global body lotions market is segmented - 1) By Type: Dry Skin Body Lotion, Oily Skin Body Lotion, Normal Skin Body Lotion, Others 2) By Application: Men, Women, Baby 3) By Channel: Direct Sales, Distributor